2021
Sex-based disparity in paraoxonase-2 expression in the brains of African green monkeys
Jamwal S, Blackburn JK, Elsworth JD. Sex-based disparity in paraoxonase-2 expression in the brains of African green monkeys. Free Radical Biology And Medicine 2021, 167: 201-204. PMID: 33722626, PMCID: PMC8096713, DOI: 10.1016/j.freeradbiomed.2021.03.003.Peer-Reviewed Original ResearchConceptsAfrican green monkeysParaoxonase 2Parkinson's diseaseBrain regionsGreen monkeysOxidative stressReactive oxygen speciesAnti-inflammatory propertiesSex-based disparitiesParaoxonase-2 expressionDifferent brain regionsNigrostriatal systemPON2 expressionDevelopment of therapeuticsNeurodegenerative disordersDiseaseProtein levelsROS levelsLower ROS levelsMitochondrial performanceSex-based variationDisordersMonkeysOxygen speciesMales
2020
PPARγ/PGC1α signaling as a potential therapeutic target for mitochondrial biogenesis in neurodegenerative disorders
Jamwal S, Blackburn J, Elsworth JD. PPARγ/PGC1α signaling as a potential therapeutic target for mitochondrial biogenesis in neurodegenerative disorders. Pharmacology & Therapeutics 2020, 219: 107705. PMID: 33039420, PMCID: PMC7887032, DOI: 10.1016/j.pharmthera.2020.107705.Peer-Reviewed Original ResearchConceptsNeurodegenerative disordersParkinson's diseaseAlzheimer's diseaseParaoxonase 2Mitochondrial biogenesisNeurodegenerative diseasesHuntington's diseasePeroxisome proliferator-activated receptorProliferator-activated receptorPotential therapeutic targetDevastating neurological disorderFunction of neuronsPeroxisome proliferator-activated receptor gamma co-activator-1 alphaPharmacological-based therapiesSymptomatic treatmentCurrent therapiesClinical trialsLigand-inducible transcription factorsTherapeutic targetNeurological disordersDiseasePPARγ modulatorsProgressive lossMitochondrial dysfunctionPromising targetPioglitazone activates paraoxonase-2 in the brain: A novel neuroprotective mechanism
Blackburn JK, Curry DW, Thomsen AN, Roth RH, Elsworth JD. Pioglitazone activates paraoxonase-2 in the brain: A novel neuroprotective mechanism. Experimental Neurology 2020, 327: 113234. PMID: 32044330, PMCID: PMC7089823, DOI: 10.1016/j.expneurol.2020.113234.Peer-Reviewed Original ResearchConceptsParaoxonase 2Novel neuroprotective mechanismParaoxonase-2 expressionAnti-diabetic drug pioglitazoneReactive oxygen species productionNeuroprotective strategiesNeuroprotective mechanismsBrain traumaMouse striatumOxygen species productionParkinson's diseaseAlzheimer's diseaseTherapeutic potentialPioglitazoneDiseaseOxidative stressDrug pioglitazoneSpecies productionBrainNeuroprotectionIschemiaStriatumExpressionPathologyTrauma
2015
Animal models in regenerative medicine
Bubak A, Elsworth J, Sladek J. Animal models in regenerative medicine. 2015, 301-316. DOI: 10.1002/9781118846193.ch16.Peer-Reviewed Original ResearchAnimal modelsCurrent clinical therapeuticsClinical trialsStem cellsRegenerative medicineFuture clinical trialsAppropriate animal modelsHuman therapeuticsStem cell trialsCell trialsHuman studiesClinical settingClinical therapeuticsTranslational researchUnsuccessful trialsTrialsDiseaseSpecific diseasesChallenging goalOptimal techniqueTherapeuticsCellsLoss of confidence
2009
Dopamine
Elsworth J, Roth R. Dopamine. 2009, 539-547. DOI: 10.1016/b978-008045046-9.00683-5.Peer-Reviewed Original ResearchCo-localized peptidesDA neuron activityDopamine cell groupsDendritic spine synapsesDifferent firing patternsSpine densityDA neurotransmissionSpine synapsesParkinson's diseaseNeuron activityVolume transmissionPharmacological perspectiveCell groupsFiring patternsEndogenous mechanismsDiseaseAutoreceptorsNeurotransmissionSchizophreniaBrainSynapses
2000
Estrogen Is Essential for Maintaining Nigrostriatal Dopamine Neurons in Primates: Implications for Parkinson's Disease and Memory
Leranth C, Roth R, Elsworth J, Naftolin F, Horvath T, Redmond D. Estrogen Is Essential for Maintaining Nigrostriatal Dopamine Neurons in Primates: Implications for Parkinson's Disease and Memory. Journal Of Neuroscience 2000, 20: 8604-8609. PMID: 11102464, PMCID: PMC6773080, DOI: 10.1523/jneurosci.20-23-08604.2000.Peer-Reviewed Original ResearchConceptsNigrostriatal dopamine neuronsDopamine neuronsParkinson's diseaseSubstantia nigraDopamine cellsTyrosine hydroxylase-expressing neuronsTyrosine hydroxylase-immunoreactive cellsNigral dopamine systemsEstrogen replacement therapyNew treatment strategiesUnbiased stereological analysisTypes of neuronsProgression of diseaseEstrogen replacementPostmenopausal womenEstrogen deprivationReplacement therapyTreatment strategiesCompact zoneGonadal hormonesLong-term effectsDopamine systemEstrogenDiseaseNeurons
1997
Dopamine Synthesis, Uptake, Metabolism, and Receptors: Relevance to Gene Therapy of Parkinson's Disease
Elsworth J, Roth R. Dopamine Synthesis, Uptake, Metabolism, and Receptors: Relevance to Gene Therapy of Parkinson's Disease. Experimental Neurology 1997, 144: 4-9. PMID: 9126143, DOI: 10.1006/exnr.1996.6379.Peer-Reviewed Original Research
1993
Unilateral Transplantation of Human Fetal Mesencephalic Tissue Into the Caudate Nucleus of Patients With Parkinson's Disease
SPENCER D, ROBBINS R, NAFTOLIN F, MAREK K, VOLLMER T, LERANTH C, ROTH R, PRICE L, GJEDDE A, BUNNEY B, SASS K, ELSWORTH J, KIER E, MAKUCH R, HOFFER P, REDMOND D. Unilateral Transplantation of Human Fetal Mesencephalic Tissue Into the Caudate Nucleus of Patients With Parkinson's Disease. Obstetrical & Gynecological Survey 1993, 48: 413-415. DOI: 10.1097/00006254-199306000-00013.Peer-Reviewed Original Research
1990
MPTP reduces dopamine and norepinephrine concentrations in the supplementary motor area and cingulate cortex of the primate
Elsworth J, Deutch A, Redmond D, Sladek J, Roth R. MPTP reduces dopamine and norepinephrine concentrations in the supplementary motor area and cingulate cortex of the primate. Neuroscience Letters 1990, 114: 316-322. PMID: 2402341, DOI: 10.1016/0304-3940(90)90583-u.Peer-Reviewed Original ResearchConceptsSupplementary motor areaDopamine innervationMotor areaParkinson's diseaseMPTP-induced degenerationStriatal dopamine innervationStriatal dopamine concentrationsAsymptomatic MPTPSymptomatic MPTPConcentration of dopamineNorepinephrine levelsNorepinephrine concentrationsCortical involvementDopaminergic innervationCingulate sulcusCingulate cortexMPTPCortical regionsDopamine concentrationsInnervationDiseaseDopamineBehavioral changesCortexDegenerationMPTP-induced parkinsonism: relative changes in dopamine concentration in subregions of substantia nigra, ventral tegmental area and retrorubral field of symptomatic and asymptomatic vervet monkeys
Elsworth J, Deutch A, Redmond D, Sladek J, Roth R. MPTP-induced parkinsonism: relative changes in dopamine concentration in subregions of substantia nigra, ventral tegmental area and retrorubral field of symptomatic and asymptomatic vervet monkeys. Brain Research 1990, 513: 320-324. PMID: 2350702, DOI: 10.1016/0006-8993(90)90474-p.Peer-Reviewed Original ResearchConceptsVentral tegmental areaSubstantia nigraTegmental areaRetrorubral fieldParkinson's diseasePostencephalitic Parkinson's diseaseHomovanillic acid concentrationsMesostriatal dopaminergic systemIdiopathic Parkinson's diseaseAsymptomatic monkeysSymptomatic monkeysDA neuronsHVA concentrationsMPTP toxicityTreatment regimensDopaminergic systemDopamine concentrationsDA regionsDiseaseNigraDopamineParkinsonismMonkeysVervet monkeysRegimens
1988
Biochemical analysis of caudate nucleus biopsy samples from parkinsonian patients
Goldstein M, Lieberman A, Helmer E, Koslow M, Ransohoff J, Elsworth J, Roth R, Deutch A. Biochemical analysis of caudate nucleus biopsy samples from parkinsonian patients. Annals Of Neurology 1988, 24: 685-688. PMID: 2904793, DOI: 10.1002/ana.410240517.Peer-Reviewed Original ResearchConceptsBiopsy samplesAdrenal transplantationDopamine functionAutologous adrenal transplantationMetabolite homovanillic acidEnzyme tyrosine hydroxylaseConcentration of dopamineParkinsonian patientsTherapeutic responseHomovanillic acidParkinson's diseaseTyrosine hydroxylasePostmortem valuesBiochemical analysisBiochemical parametersPatientsTransplantationPostmortem changesDiseaseReversal of Experimental Parkinsonism in African Green Monkeys Following Fetal Dopamine Neuron Transplantation
Collier T, Redmond D, Roth R, Elsworth J, Sladek J. Reversal of Experimental Parkinsonism in African Green Monkeys Following Fetal Dopamine Neuron Transplantation. 1988, 211-218. DOI: 10.1007/978-1-4613-0759-4_27.Peer-Reviewed Original ResearchChronic L-DOPA administrationL-DOPA administrationAfrican green monkeysNeuron transplantationExperimental parkinsonismMotor symptomsNigrostriatal systemBrain dopamineMotor abnormalitiesPreferred treatmentParkinson's diseaseL-DOPAGreen monkeysDiseaseProgressive debilitationNeurotransmitter dopamineAdministrationDopamineParkinsonismTransplantationSymptomsAbnormalitiesBrainSupplementation
1982
The contribution of amphetamine metabolites of (−)-deprenyl to its antiparkinsonian properties
Elsworth J, Sandler M, Lees A, Ward C, Stern G. The contribution of amphetamine metabolites of (−)-deprenyl to its antiparkinsonian properties. Journal Of Neural Transmission 1982, 54: 105-110. PMID: 6809891, DOI: 10.1007/bf01249283.Peer-Reviewed Original Research
1980
Dopamine Oxidation and Its Inhibition by (—)-Deprenyl in Man
Glover V, Elsworth J, Sandler M. Dopamine Oxidation and Its Inhibition by (—)-Deprenyl in Man. Journal Of Neural Transmission. Supplementa 1980, 163-172. PMID: 6776235, DOI: 10.1007/978-3-7091-8582-7_18.Peer-Reviewed Original Research
1979
SELECTIVE MAO INHIBITION: A NEW STRATEGY IN THE TREATMENT OF PARKINSON'S DISEASE
Elsworth J, Glover V, Sandler M. SELECTIVE MAO INHIBITION: A NEW STRATEGY IN THE TREATMENT OF PARKINSON'S DISEASE. 1979, 1575-1577. DOI: 10.1016/b978-1-4832-8363-0.50482-1.Peer-Reviewed Original Research
1977
DEPRENYL IN PARKINSON'S DISEASE
Lees A, Kohout L, Shaw K, Stern G, Elsworth J, Sandler M, Youdim M. DEPRENYL IN PARKINSON'S DISEASE. The Lancet 1977, 310: 791-795. PMID: 71602, DOI: 10.1016/s0140-6736(77)90725-5.Peer-Reviewed Original ResearchConceptsParkinson's diseaseDouble-blind crossover trialDoses of levodopaEarly morning akinesiaPeripheral decarboxylase inhibitorLevodopa-induced dyskinesiaTotal daily dosesMajority of patientsIdiopathic Parkinson's diseaseDose akinesiaUntreated patientsCrossover trialDosage reductionDaily dosesDecarboxylase inhibitorTherapeutic effectCheese effectLarge dosesPatientsLevodopaAlternate daysAkinesiaDeprenylDiseaseB inhibitor